Document is current
Any future updates will be listed below
-
Authors
Saxena, Kapil
Jabbour, Elias
Issa, Ghayas
Sasaki, Koji
Ravandi, Farhad
Maiti, Abhishek
Daver, Naval
Kadia, Tapan
DiNardo, Courtney D.
Konopleva, Marina
Cortes, Jorge E.
Yilmaz, Musa
Chien, Kelly
Pierce, Sherry
Kantarjian, Hagop
Short, Nicholas J. http://orcid.org/0000-0002-2983-2738
-
Funding
Funding for this research was provided by:
University of Texas MD Anderson Cancer Center (CA016672)
National Institutes of Health (K12 Paul Calabresi Clinical Oncology Scholar Award)
American Society of Hematology (Junior Faculty Scholar Award in Clinical Research)
- License Information
-
More Information
Article History
Received: 19 April 2021
Accepted: 7 June 2021
First Online: 15 June 2021
Declarations
:
: The retrospective study was conducted at a single academic medical center (The University of Texas MD Anderson Cancer Center), approved by the Institutional Review Board, and conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: N.J.S has served as a consultant for Takeda Oncology, AstraZeneca and Jazz Pharmaceuticals, reports receiving research grants from Takeda Oncology and Astellas Pharma Inc., and has received honoraria from Amgen. The other authors report no relevant conflicts of interest.
